Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Gilenya Approved With Advisory Panel-Enhanced REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.
Advertisement

Related Content

Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Novartis' Gilenya Shines Amid Bleak Day for MS Drugs In Europe
Teva's Laquinimod Meets Primary Endpoint In First Phase III Study
“Defensive REMS” May Be Needed To Appease Advisory Committees
Gilenya Could Surpass Avonex Market Share, Analysts Say
Sales of Acorda's Ampyra Off To Strong Start
Humana Coverage Policy For Gilenya Promotes Second-Line Use
Gilenia's Risk Management Should Key On Initial Doctor Visit, Cmte. Says
Gilenia's Risk Management Should Key On Initial Doctor Visit, Cmte. Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS071215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel